Status:
TERMINATED
Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
Lead Sponsor:
Novartis
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months
Eligibility Criteria
Inclusion
- Histologically documented diagnosis of GBM.
- Immunohistochemical documentation of expression of PDGFR.
- Unresectable, recurrent disease by MRI and spectroscopy
Exclusion
- Treatment with any other investigational agents within 28 days of first day of study drug dosing.
- Concurrent chemotherapy.
- Concurrent radiotherapy.
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00171938
Start Date
April 1 2004
End Date
June 1 2006
Last Update
February 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rio Grande, Brazil